Table S1 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.22412469

2023-01-01

Abstract:An MS Excel file listing Response Modules

What problem does this paper attempt to address?

Tabel S2 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.22412472.v1

2023-01-01

Abstract:An MS Excel file containing the response modules that are highly informative of patient outcome.
Table S5 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.22412463

2023-01-01

Abstract:An MS Word file containing the genes in a perturbation module that regulate the expression of a response module annotated with GO:001251 (programmed cell death) and the literature associated with the genes.
Table S4 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.22412466.v1

2023-01-01

Abstract:An MS Word file contain the genes in a response module annotated GO:0016477 (cell migration) and the literature associated with the genes
Supplementary Figures, Results, and Methods from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.22412475.v1

2023-01-01

Abstract:Supplementary figures, results, and methods.
Signal-Oriented Pathway Analyses Reveal a Signaling Complex As a Synthetic Lethal Target for P53 Mutations

Songjian Lu,Chunhui Cai,Gonghong Yan,Zhuan Zhou,Yong Wan,Vicky Chen,Lujia Chen,Gregory F. Cooper,Lina M. Obeid,Yusuf A. Hannun,Adrian V. Lee,Xinghua Lu

DOI: https://doi.org/10.1158/0008-5472.can-16-1740

2023-01-01

Abstract:Abstract Defining processes that are synthetic lethal with p53 mutations in cancer cells may reveal possible therapeutic strategies. In this study, we report the development of a signal-oriented computational framework for cancer pathway discovery in this context. We applied our bipartite graph–based functional module discovery algorithm to identify transcriptomic modules abnormally expressed in multiple tumors, such that the genes in a module were likely regulated by a common, perturbed signal. For each transcriptomic module, we applied our weighted k-path merge algorithm to search for a set of somatic genome alterations (SGA) that likely perturbed the signal, that is, the candidate members of the pathway that regulate the transcriptomic module. Computational evaluations indicated that our methods-identified pathways were perturbed by SGA. In particular, our analyses revealed that SGA affecting TP53, PTK2, YWHAZ, and MED1 perturbed a set of signals that promote cell proliferation, anchor-free colony formation, and epithelial–mesenchymal transition (EMT). These proteins formed a signaling complex that mediates these oncogenic processes in a coordinated fashion. Disruption of this signaling complex by knocking down PTK2, YWHAZ, or MED1 attenuated and reversed oncogenic phenotypes caused by mutant p53 in a synthetic lethal manner. This signal-oriented framework for searching pathways and therapeutic targets is applicable to all cancer types, thus potentially impacting precision medicine in cancer. Cancer Res; 76(23); 6785–94. ©2016 AACR.
Figure S1 from Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors

Michael K. Asiedu,Charles F. Thomas,Jie Dong,Sandra C. Schulte,Prasidda Khadka,Zhifu Sun,Farhad Kosari,Jin Jen,Julian Molina,George Vasmatzis,Ray Kuang,Marie Christine Aubry,Ping Yang,Dennis A. Wigle

DOI: https://doi.org/10.1158/1078-0432.22465187.v1

2023-01-01

Abstract:Pathway analysis of significantly mutated genes
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai Tran,Robert J.G. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun K. Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22446704

2023-01-01

Abstract:PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death

Joshua H. Choe,Tatsuya Kawase,An Xu,Asja Guzman,Aleksandar Z. Obradovic,Ana Maria Low-Calle,Bita Alaghebandan,Ananya Raghavan,Kaitlin Long,Paul M. Hwang,Joshua D. Schiffman,Yan Zhu,Ruiying Zhao,Dung-Fang Lee,Chen Katz,Carol Prives

DOI: https://doi.org/10.1158/2159-8290.22645252

2023-01-01

Abstract:Differentially expressed genes in U2OS cells varying in p53 allelic status combined from two independent RNA library preparations
Supplementary Table S1 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Zhi Shi,Hae R. Park,Yuhong Du,Zijian Li,Kejun Cheng,Shi-Yong Sun,Zenggang Li,Haian Fu,Fadlo R. Khuri

DOI: https://doi.org/10.1158/0008-5472.22404702

2023-01-01

Abstract:Supplementary Table S1. 14-3-3y-associated proteins from A549 lung cancer cells.
Supplementary Table S2 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Zhi Shi,Hae R. Park,Yuhong Du,Zijian Li,Kejun Cheng,Shi-Yong Sun,Zenggang Li,Haian Fu,Fadlo R. Khuri

DOI: https://doi.org/10.1158/0008-5472.22404699

2023-01-01

Abstract:Supplementary Table S2. Human lung tumor sample histology information and IHC scoring summary.
Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants

Dhruv Chachad,Lalit R. Patel,Carlos Vera Recio,Rasoul Pourebrahim,Elizabeth M. Whitley,Wenyi Wang,Xiaoping Su,An Xu,Dung-Fang Lee,Guillermina Lozano

DOI: https://doi.org/10.1158/0008-5472.23684074.v1

2023-01-01

Abstract:Pulmonary metastasis in p53 mutant mice
Global Investigation of p53-induced Apoptosis Through Quantitative Proteomic Profiling Using Comparative Amino Acid-coded Tagging

Sheng Gu,Zhihe Liu,Songqin Pan,Zeyu Jiang,Huimei Lu,Or Amit,E Morton Bradbury,Chien-An A Hu,Xian Chen

DOI: https://doi.org/10.1074/mcp.M400033-MCP200

IF: 7.381

2004-01-01

Molecular & Cellular Proteomics

Abstract:p53-induced apoptosis plays a pivotal role in the suppression of tumorigenesis, and mutations in p53 have been found in more than 50% of human tumors. By comparing the proteome of a human colorectal cancer cell transfected with inducible p53 (DLD-1.p53) with that of the control DLD-1 cell line using amino acid-coded mass tagging (AACT)-assisted mass spectrometry, we have broadly identified proteins that are upregulated at the execution stage of the p53-mediated apoptosis. In cell culturing, the deuterium-labeled ( heavy) amino acids were incorporated into the proteome of the induced DLD-1. p53 cells, whereas the DLD-1. vector cells were grown in the unlabeled medium. In high-throughput LC-ESI-MS/MS analyses, the AACT-containing peptides were paired with their unlabeled counterparts, and their relative spectral intensities, reflecting the differential protein expression, were quantified. In addition, our novel AACT-MS method utilized a number of different heavy amino acids as internal markers that significantly increased the peptide sequence coverage for both quantitation and identification purposes. As a result, we were able to identify differentially regulated protein isozymes that would be difficult to distinguish by ICAT-MS methods and to obtain a large dataset of the proteins with altered expression in the late stage of p53-induced apoptosis. The regulated proteins we identified are associated with several distinct functional categories: cell cycle arrest and p53 binding, protein chaperoning, plasma membrane dynamics, stress response, antioxidant enzymes, and anaerobic glycolysis. This result suggests that the p53-induced apoptosis involves the systematic activation of multiple pathways that are glycolysis-relevant, energy-dependent, oxidative stress-mediated, and possibly mediated through interorganelle crosstalks.
Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Wenge Wang,Seok-Hyun Kim,Wafik S El-Deiry

DOI: https://doi.org/10.1073/pnas.0604507103

2006-01-01

Abstract:p53 deficiency is common in almost all human tumors and contributes to an aggressive chemo- or radiotherapy-resistant phenotype, therefore providing a target for drug development. Molecular targeting to restore wild-type p53 activity has been attempted in drug development and has led to the identification of CP-311398, PRIMA1, and the Nutlins. However, strategies targeting p53-activated transcriptional responses or p53 family member expression in p53-deficient tumors have yet to be explored. Here we demonstrate the use of noninvasive bioluminescence imaging in a high-throughput cell-based screen of small molecules that activate p53 responses and cell death in human tumor cells carrying a mutant p53. We isolated a number of small molecules that activate p53 reporter activity, increase expression of p53 target genes such as p21(WAF1) or death receptor 5 (KILLER/DR5) of TNF-related apoptosis-inducing ligand (TRAIL), and induce apoptosis in p53-deficient cells. Some of the compounds activate a p53 response by increasing p73 expression, and knockdown of transactivating isoforms of p73 by small interfering RNA reduces their induction of p53-responsive transcriptional activity. Some compounds do not induce significant p73 expression but induce a high p53-responsive transcriptional activity in the absence of p53. In vivo experiments demonstrate potent antitumor effects of selected compounds, using either HCT116/p53(-/-) or DLD1 human colon tumor xenografts. The results establish the feasibility of a cell-based drug screening strategy targeting the p53 transcription factor family of importance in human cancer and provide lead compounds for further development in cancer therapy.
Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different P53 Mutants

Dhruv Chachad,Lalit R. Patel,Carlos Vera Recio,Rasoul Pourebrahim,Elizabeth M. Whitley,Wenyi Wang,Xiaoping Su,An Xu,Dung-Fang Lee,Guillermina Lozano

DOI: https://doi.org/10.1158/0008-5472.23684071

2023-01-01

Abstract:Gene annotation performed by HOMER of p53 ChIP peaks from WT p53 osteoblasts
Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different P53 Mutants

Dhruv Chachad,Lalit R. Patel,Carlos Vera Recio,Rasoul Pourebrahim,Elizabeth M. Whitley,Wenyi Wang,Xiaoping Su,An Xu,Dung-Fang Lee,Guillermina Lozano

DOI: https://doi.org/10.1158/0008-5472.23684077

2023-01-01

Abstract:List of mice belonging to different cohorts
Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Matheus Henrique Dias,Anoek Friskes,Siying Wang,Joao M. Fernandes Neto,Frank van Gemert,Soufiane Mourragui,Chrysa Papagianni,Hendrik J. Kuiken,Sara Mainardi,Daniel Alvarez-Villanueva,Cor Lieftink,Ben Morris,Anna Dekker,Emma van Dijk,Lieke H.S. Wilms,Marcelo S. da Silva,Robin A. Jansen,Antonio Mulero-Sánchez,Elke Malzer,August Vidal,Cristina Santos,Ramón Salazar,Rosangela A.M. Wailemann,Thompson E.P. Torres,Giulia De Conti,Jonne A. Raaijmakers,Petur Snaebjornsson,Shengxian Yuan,Wenxin Qin,John S. Kovach,Hugo A. Armelin,Hein te Riele,Alexander van Oudenaarden,Haojie Jin,Roderick L. Beijersbergen,Alberto Villanueva,Rene H. Medema,Rene Bernards

DOI: https://doi.org/10.1158/2159-8290.26134828

2024-01-01

Abstract:Supplementary table 3: Full list of genes whose knockout attenuated LB-100 toxicity in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change greater or equal to 1 in treated/untreated comparison were criteria for hit selection.

Table S1 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Tabel S2 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Table S5 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Table S4 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Supplementary Figures, Results, and Methods from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Signal-Oriented Pathway Analyses Reveal a Signaling Complex As a Synthetic Lethal Target for P53 Mutations

Figure S1 from Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death

Supplementary Table S1 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Supplementary Table S2 from Cables1 Complex Couples Survival Signaling to the Cell Death Machinery

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants

Global Investigation of p53-induced Apoptosis Through Quantitative Proteomic Profiling Using Comparative Amino Acid-coded Tagging

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different P53 Mutants

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different P53 Mutants

Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy